Biologics Manufacturing Core

此SPORE应用程序的生物制剂制造核心致力于临床试验的生产 根据各个项目和所有适用状态中概述的方案要求提供材料， 当地和联邦法规。核心分为三个生产组; 细胞产品、单克隆抗体和病毒载体。每个小组由一名具有广泛 临床试验材料和良好生产规范（GMP）的生产经验。每个 集团由质量体系团队（质量保证和质量控制）提供支持，以确保 试验用药品生产的检测和记录根据适用的 规定生产将在两个地点进行。生物医学和遗传学中心（CBG）和 细胞医学实验室（LCM）生产设施位于新的Arnold和美宝贝克曼中心 2009年完成的癌症免疫治疗和肿瘤免疫学。单克隆抗体和 项目1、3和4的构建体和项目1的病毒载体将在CBG中生产，而细胞 项目1的产品将在LCM中制造。在过去的五年中，单克隆抗体 产品已经为以前的SPORE项目1、2、4和5生产，其中一些已经 用于临床试验。MAb生产、结合和装瓶程序的广泛开发 产品已经发生。一种以临床规模量偶联单克隆抗体的新方法已经被发现， 最近开发并出版。细胞医学实验室（LCM）已经生产出 对于孢子项目2（滤泡性淋巴瘤的免疫治疗）的先前迭代， 目前生产用于套细胞/DLBC淋巴瘤的产品（项目1）。广泛进程 已经在封闭系统细胞处理、细胞选择、基于慢病毒的 基因修饰和扩增，为生产研究性细胞产品做准备， 淋巴瘤和其他血液恶性肿瘤。已生产质粒DNA和病毒载体 滤泡性淋巴瘤和套细胞/DLBC淋巴瘤方案，目前正在开发， 治疗非霍奇金淋巴瘤患者的孢子项目1。

The Biologics Manufacturing core for this SPORE application is dedicated to the production of clinical trial materials according to programmatic requirements outlines in the individual projects and all applicable state, local and Federal regulations for investigational products. The core is divided into three production groups; cell products, monoclonal antibodies and viral vectors. Each group is led by a Director with extensive experience in the production of clinical trials materials and Good Manufacturing Practices (GMP). Each group is supported by a Quality Systems Team (Quality Assurance and Quality Control) that ensures that testing and documentation of investigational product manufacturing is performed according to the applicable regulations. Manufacturing will occur at two sites. The Center for Biomedicine and Genetics (CBG) and the Laboratory for Cellular Medicine (LCM) manufacturing facility in the new Arnold and Mabel Beckman Center for Cancer Immunotherapeutics and Tumor Immunology completed in 2009. Monoclonal antibodies and constructs for Projects 1, 3 and 4 and Viral vectors for Project 1 will be manufactured in the CBG while cell products for Project 1 will be manufactured in the LCM. Over the past five years monoclonal antibody products have been produced for the previous SPORE Projects 1,2,4 and 5, some of which have been used in clinical trials. Extensive development of manufacturing, conjugating and vialing procedures for MAb products has taken place. A new method for the conjugation of MAbs at clinical scale quantities has been developed and recently published. The Laboratory for Cellular Medicine (LCM) has manufactured products for the previous iteration of SPORE Project 2 (Adoptive Immunotherapy for Follicular Lymphoma), is currently manufacturing products for Mantle Cell/DLBC Lymphoma (Project 1). Extensive process development has taken place in the areas of closed system cell processing, cell selection, lentiviral-based genetic modification and expansion in preparation for manufacturing investigational cell products for Lymphoma and other hematological malignancies. Plasmid DNA and Viral vectors have been manufactured for Follicular Lymphoma and Mantle Cell/DLBC Lymphoma protocols and are currently being developed for treating NHL patients for SPORE Project 1.